XML 46 R34.htm IDEA: XBRL DOCUMENT
v3.20.2

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | $ 57,763 | $ 21,958 | $ 92,392 | $ 47,577
Biogen MA, Inc. |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 9,621 | 0 | 17,799 | 0
Biogen MA, Inc. | Collaboration Agreements |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 7,306 | 0 | 14,050 | 0
Biogen MA, Inc. | Research services |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 2,315 | 0 | 3,749 | 0
Kite Pharma Inc |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 7,294 | 8,861 | 21,935 | 26,233
Kite Pharma Inc | Collaboration Agreements |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 6,296 | 6,296 | 18,750 | 18,682
Kite Pharma Inc | Research services |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 998 | 2,565 | 3,185 | 7,551
Pfizer SB-525 |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 30,084 | 3,440 | 33,696 | 5,035
Pfizer SB-525 | Collaboration Agreements |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 221 | 3,440 | 2,737 | 5,035
Pfizer SB-525 | Milestone Achievement |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 29,863 | 0 | 30,959 | 0
Pfizer |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 9,200 | 468 | 12,985 | 1,538
Pfizer | Collaboration Agreements |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 4,200 | 468 | 7,985 | 1,538
Pfizer | Milestone Achievement |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 5,000 | 0 | 5,000 | 0
Sanofi |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 1,498 | 2,754 | 3,789 | 7,763
Sanofi | Collaboration Agreements |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 321 | 940 | (28) | 2,594
Sanofi | Research services |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | 961 | 1,814 | 3,836 | 5,169
Sanofi | Milestone Achievement |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Revenues | $ 216 | $ 0 | $ (19) | $ 0

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_ResearchServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerSB525Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_SanofiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |